Montreal (Nov11, 2014) — OsteoQC a company devoted to developing therapies for the treatment of bone-re- lated diseases today announced the closing of a seed financing round. Lumira Capital Investment Management via its Merck Lumira Biosciences Fund led the financing, which represents part of Lumira’s ongoing strategy to build early stage highly innovative health care technology companies with significant growth potential in Quebec. OsteoQC is a newly formed company, based in Montreal that will develop new drug candidates for the treatment of bone-related diseases. Through its collaboration with OsteoGeneX, based in Overland Park, KS, OsteoQC has ac- quired a rich intellectual property portfolio supporting proprietary product candidates for promoting bone growth. The company will be led by Dr. Debra Ellies, a world expert in the area of bone formation “This financing round enables us to rapidly advance our lead small molecule product candidate for bone formation”, said Dr. Ellies. “Que- bec has a rich ecosystem of medicinal chemistry and highly qualified pharmaceutical scientists and we will look forward to building this company in such a rich environment.” “The foundational work already accomplished by OsteoGeneX and Dr. Ellies provides a great launching pad to es- tablish OsteoQC in Montreal” commented Dr. Daniel Hetu, Managing Director of Lumira Capital and Vice-Chair of OsteoQC. Dr. Brian Underdown, Managing Director of Lumira Capital and Chairman of OsteoQC said “Lumira’s intention is to build OsteoQC as a leading company devoted to unmet needs in bone-related diseases”. About Lumira Capital Lumira Capital is a leading North American healthcare and life sciences venture capital firm. Currently managing over $250 million, Lumira Capital is an active investor that works closely with entrepreneurs to develop transforma- tive therapeutics and medical technology innovations. Previous Lumira Capital investments include Thrasos Thera- peutics, enGene Inc., Pharmasset (acquired by Gilead Sciences), Ception Therapeutics (acquired by Cephalon), Resonant Medical (acquired by Elekta), Morphotek (acquired by Eisai), and Corus Pharma (acquired by Gilead Sci- ences), as well as public companies such as MAKO Surgical (acquired by Stryker Corp.), DepoMed, and Ista Phar- maceuticals. Lumira Capital has partners in Toronto, Montréal and Boston. About OsteoGeneX OsteoGeneX is a private, Kansas-based company focused on developing therapies to promote bone healing. In ad- ditional to its collaboration with OsteoQC, OsteoGeneX will continue its work to develop implantable devices to promote fracture healing. For more information, contact: Lumira Capital Daniel Hetu Managing Director, Lumira Capital 1.514.844-6927 OsteoGeneX Debra Ellies President and CEO 1.913.660.0637

Montreal (Nov11, 2014) — OsteoQC a company devoted to developing therapies for the treatment of bone-re- lated diseases today announced the closing of a seed financing round. Lumira Capital Investment Management via its Merck Lumira Biosciences Fund led the financing, which represents part of Lumira’s ongoing strategy to build early stage highly innovative health care technology companies with significant growth potential in Quebec. OsteoQC is a newly formed company, based in Montreal that will develop new drug candidates for the treatment of bone-related diseases. Through its collaboration with OsteoGeneX, based in Overland Park, KS, OsteoQC has ac- quired a rich intellectual property portfolio supporting proprietary product candidates for promoting bone growth. The company will be led by Dr. Debra Ellies, a world expert in the area of bone formation “This financing round enables us to rapidly advance our lead small molecule product candidate for bone formation”, said Dr. Ellies. “Que- bec has a rich ecosystem of medicinal chemistry and highly qualified pharmaceutical scientists and we will look forward to building this company in such a rich environment.” “The foundational work already accomplished by OsteoGeneX and Dr. Ellies provides a great launching pad to es- tablish OsteoQC in Montreal” commented Dr. Daniel Hetu, Managing Director of Lumira Capital and Vice-Chair of OsteoQC. Dr. Brian Underdown, Managing Director of Lumira Capital and Chairman of OsteoQC said “Lumira’s intention is to build OsteoQC as a leading company devoted to unmet needs in bone-related diseases”. About Lumira Capital Lumira Capital is a leading North American healthcare and life sciences venture capital firm. Currently managing over $250 million, Lumira Capital is an active investor that works closely with entrepreneurs to develop transforma- tive therapeutics and medical technology innovations. Previous Lumira Capital investments include Thrasos Thera- peutics, enGene Inc., Pharmasset (acquired by Gilead Sciences), Ception Therapeutics (acquired by Cephalon), Resonant Medical (acquired by Elekta), Morphotek (acquired by Eisai), and Corus Pharma (acquired by Gilead Sci- ences), as well as public companies such as MAKO Surgical (acquired by Stryker Corp.), DepoMed, and Ista Phar- maceuticals. Lumira Capital has partners in Toronto, Montréal and Boston. About OsteoGeneX OsteoGeneX is a private, Kansas-based company focused on developing therapies to promote bone healing. In ad- ditional to its collaboration with OsteoQC, OsteoGeneX will continue its work to develop implantable devices to promote fracture healing. For more information, contact: Lumira Capital Daniel Hetu Managing Director, Lumira Capital 1.514.844-6927 OsteoGeneX Debra Ellies President and CEO 1.913.660.0637